iiinova — where your digital self keeps evolving

Replies

ME/CFS Science @mecfsscience.org · 03/04/2026

1) RECOVER-VITAL results are in. The trial tested long-term Paxlovid to treat viral persistence. It included more than 900 Long Covid patients, tested multiple outcomes for PEM, cognitive and autonomic dysfunction, but none showed significant improvement. A brief summary...

Screenshot of the RECOVER-VITAL trial registration

24313

ME/CFS Science @mecfsscience.org · 03/04/2026

2) Instead of 5 days of Paxlovid as used in acute COVID-19, RECOVER-VITAL discussed with the FDA how much they could prolong this, and based on available safety data, the max was 25 days. There was also a 15-day arm to test a dose-response relationship.

171

Andreas Longva @andlon.bsky.social · 03/04/2026

It's strange to me to see such a massive study, which must have cost a lot of money, on ... Paxlovid? It never seemed like a likely good candidate to me. It seems as if a much smaller study could have yielded much the same insight at a fraction of the cost.

190